Literature DB >> 20477422

Assessment of soluble angiogenic markers in pancreatic cancer.

Cristiana Pistol-Tanase1, Elena Raducan, Simona Olimpia Dima, Lucian Albulescu, Ionita Alina, Poroschianu Marius, Linda Maria Cruceru, Eleonora Codorean, Teodora Monica Neagu, Irinel Popescu.   

Abstract

UNLABELLED: Angiogenic markers such as VEGF/basic FGF (bFGF) can enlarge the diagnostic biomarkers panel for pancreatic cancer. MATERIALS &
METHODS: Serum samples from 32 stage I-IV pancreatic cancer patients and 20 controls were analyzed for soluble VEGF/bFGF by ELISA and xMAP array.
RESULTS: VEGF/bFGF serum levels were significantly increased in patients compared with controls (p < 0.0001). We report a correlation with tumor diameter (p < 0.01/p < 0.05), stage (p < 0.001), Ki67LI (p < 0.005/p < 0.05) and carbohydrate 19-9 antigen (p < 0.005/p < 0.001). VEGF/bFGF levels analyzed by xMAP array were comparable with the pattern (patient/control) outline obtained by ELISA tests. We obtained a good correlation between these two soluble angiogenic markers (p < 0.001).
CONCLUSION: Data obtained for angiogenic markers qualifies them as important candidates in the pancreatic cancer biomarker panel.

Entities:  

Year:  2008        PMID: 20477422     DOI: 10.2217/17520363.2.5.447

Source DB:  PubMed          Journal:  Biomark Med        ISSN: 1752-0363            Impact factor:   2.851


  12 in total

Review 1.  Molecular biology of pancreatic ductal adenocarcinoma progression: aberrant activation of developmental pathways.

Authors:  Andrew D Rhim; Ben Z Stanger
Journal:  Prog Mol Biol Transl Sci       Date:  2010       Impact factor: 3.622

Review 2.  Early diagnosis of pancreatic cancer: challenges and new developments.

Authors:  Sukhwinder Kaur; Michael J Baine; Maneesh Jain; Aaron R Sasson; Surinder K Batra
Journal:  Biomark Med       Date:  2012-10       Impact factor: 2.851

Review 3.  Circulating biomarkers for early diagnosis of pancreatic cancer: facts and hopes.

Authors:  Xu Zhang; Si Shi; Bo Zhang; Quanxing Ni; Xianjun Yu; Jin Xu
Journal:  Am J Cancer Res       Date:  2018-03-01       Impact factor: 6.166

Review 4.  Myokines as Possible Therapeutic Targets in Cancer Cachexia.

Authors:  Emilia Manole; Laura C Ceafalan; Bogdan O Popescu; Carmen Dumitru; Alexandra E Bastian
Journal:  J Immunol Res       Date:  2018-10-22       Impact factor: 4.818

Review 5.  Inflammation-Related Mechanisms in Chronic Kidney Disease Prediction, Progression, and Outcome.

Authors:  Simona Mihai; Elena Codrici; Ionela Daniela Popescu; Ana-Maria Enciu; Lucian Albulescu; Laura Georgiana Necula; Cristina Mambet; Gabriela Anton; Cristiana Tanase
Journal:  J Immunol Res       Date:  2018-09-06       Impact factor: 4.818

6.  Inflammatory cytokines and combined biomarker panels in pancreatic ductal adenocarcinoma: Enhancing diagnostic accuracy.

Authors:  Deirdré Kruger; Yandiswa Y Yako; John Devar; Nicola Lahoud; Martin Smith
Journal:  PLoS One       Date:  2019-08-15       Impact factor: 3.240

7.  Insulin-like growth factor 2 mRNA-binding protein 1 promotes cell proliferation via activation of AKT and is directly targeted by microRNA-494 in pancreatic cancer.

Authors:  Bai-Shun Wan; Ming Cheng; Ling Zhang
Journal:  World J Gastroenterol       Date:  2019-10-28       Impact factor: 5.742

8.  The Hemostasis Apparatus in Pancreatic Cancer and Its Importance beyond Thrombosis.

Authors:  Hussein Echrish; Leigh A Madden; John Greenman; Anthony Maraveyas
Journal:  Cancers (Basel)       Date:  2011-01-11       Impact factor: 6.639

9.  Cytokine patterns in brain tumour progression.

Authors:  Radu Albulescu; Elena Codrici; Ionela Daniela Popescu; Simona Mihai; Laura Georgiana Necula; Daniel Petrescu; Mihaela Teodoru; Cristiana Pistol Tanase
Journal:  Mediators Inflamm       Date:  2013-06-24       Impact factor: 4.711

10.  Proteomic Biomarkers Panel: New Insights in Chronic Kidney Disease.

Authors:  Simona Mihai; Elena Codrici; Ionela Daniela Popescu; Ana-Maria Enciu; Elena Rusu; Diana Zilisteanu; Radu Albulescu; Gabriela Anton; Cristiana Tanase
Journal:  Dis Markers       Date:  2016-09-07       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.